Tweenvest Stocks

AN2 Therapeutics, Inc. (NasdaqGS: ANTX)

Health Care · Pharmaceuticals · US

$5.63

-3.10% today · +416.4% 1Y

AN2 Therapeutics, Inc. (NasdaqGS: ANTX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $219.25M and employs 21 people.

Over the last twelve months the share price has gained 416.4%, trading between 1.00 and 7.19.

Tweenvest scores AN2 Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.

ANTX price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$219.25M
Revenue (TTM)
P/E
EPS
-1.04
Dividend yield
Beta (5Y)
-0.99
52-week high
$7.19
52-week low
$1.00
Avg volume (3M)
Shares outstanding
37.74M
Employees
21
Next earnings

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

ISIN
US0373261058
Founded
2017
Listed since
Mar 25, 2022
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.12T$1,246.93-0.67%
Johnson & JohnsonNYSE: JNJ$651.25B$273.04+1.04%
Merck & Co., Inc.NYSE: MRK$376.37B$150.66-1.24%
Roche Holding AGSWX: ROP$373.91BCHF370.40-1.38%
Novartis AGSWX: NOVN$302.17BCHF127.42+0.85%
AstraZeneca PLCLSE: AZN$258.76B£121.10-1.06%
Novo Nordisk A/SCPSE: NOVO B$207.84BDkr300.85+1.59%
Pfizer Inc.NYSE: PFE$159.99B$27.97-0.36%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.